N17 Modifies Mutant Huntingtin Nuclear Pathogenesis and Severity of Disease in HD BAC Transgenic Mice

Neuron

Volumn 85, Issue 4, 2015, Pages 726-741

  Gu, Xiaofeng ^a,b   Cantle, Jeffrey P ^a,b   Greiner, Erin R ^a,c   Lee, C Y Daniel ^a,b   Barth, Albert M ^b   Gao, Fuying ^a,b   Park, Chang Sin ^a,b   Zhang, Zhiqiang ^d,e   Sandoval Miller, Susana ^a,b   Zhang, Richard L ^a,b   Diamond, Marc ^d,e   Mody, Istvan ^b   Coppola, Giovanni ^a,b   Yang, X William ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 6; HUNTINGTIN; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN WEIGHT; CELL LOSS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; FEMALE; GAIT DISORDER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEAD MOVEMENT; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION; WEIGHT REDUCTION; AGE; ANIMAL; BRAIN; CELL FRACTIONATION; COMPLICATION; DISEASE MODEL; GENETICS; HEK293 CELL LINE; HUMAN; LOCOMOTION; METABOLISM; NERVE CELL; NUCLEOLUS; ORGAN SIZE; PATHOLOGY; PHENOTYPE; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT; ULTRASTRUCTURE;

AGE FACTORS; ANIMALS; BRAIN; CELL NUCLEOLUS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; LOCOMOTION; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; ORGAN SIZE; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; SUBCELLULAR FRACTIONS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84925657284     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.01.008     Document Type: Article

References (62)

1. Atwal R.S., Xia J., Pinchev D., Taylor J., Epand R.M., Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 2007, 16:2600-2615.
2. Atwal R.S., Desmond C.R., Caron N., Maiuri T., Xia J., Sipione S., Truant R. Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat. Chem. Biol. 2011, 7:453-460.
3. Benn C.L., Landles C., Li H., Strand A.D., Woodman B., Sathasivam K., Li S.H., Ghazi-Noori S., Hockly E., Faruque S.M., et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum. Mol. Genet. 2005, 14:3065-3078.
4. Björkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R.V., Benn C.L., Soulet D., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J.Exp. Med. 2008, 205:1869-1877.
5. Burgess D.L., Noebels J.L. Single gene defects in mice: the role of voltage-dependent calcium channels in absence models. Epilepsy Res. 1999, 36:111-122.
6. Cayzac S., Delcasso S., Paz V., Jeantet Y., Cho Y.H. Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington disease. Proc. Natl. Acad. Sci. USA 2011, 108:9280-9285.
7. Ch'ng T.H., Uzgil B., Lin P., Avliyakulov N.K., O'Dell T.J., Martin K.C. Activity-dependent transport of the transcriptional coactivator CRTC1 from synapse to nucleus. Cell 2012, 150:207-221.
8. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
9. Dehay B., Weber C., Trottier Y., Bertolotti A. Mapping of the epitope of monoclonal antibody 2B4 to the proline-rich region of human Huntingtin, a region critical for aggregation and toxicity. Biotechnol. J. 2007, 2:559-564.
10. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
11. Dunah A.W., Wyszynski M., Martin D.M., Sheng M., Standaert D.G. alpha-actinin-2 in rat striatum: localization and interaction with NMDA glutamate receptor subunits. Brain Res. Mol. Brain Res. 2000, 79:77-87.
12. Geschwind D.H., Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature 2009, 461:908-915.
13. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
14. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
15. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J.Neurosci. 2008, 28:6182-6195.
16. Grimbergen Y.A.M., Knol M.J., Bloem B.R., Kremer B.P.H., Roos R.A.C., Munneke M. Falls and gait disturbances in Huntington's disease. Mov. Disord. 2008, 23:970-976.
17. Gu X., Greiner E.R., Mishra R., Kodali R., Osmand A., Finkbeiner S., Steffan J.S., Thompson L.M., Wetzel R., Yang X.W. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009, 64:828-840.
18. Gunawardena S., Her L.-S., Brusch R.G., Laymon R.A., Niesman I.R., Gordesky-Gold B., Sintasath L., Bonini N.M., Goldstein L.S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40:25-40.
19. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J.Neurosci. 1999, 19:2522-2534.
20. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
21. Jayaraman M., Mishra R., Kodali R., Thakur A.K., Koharudin L.M., Gronenborn A.M., Wetzel R. Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties. Biochemistry 2012, 51:2706-2716.
22. Karch C.M., Cruchaga C., Goate A.M. Alzheimer's disease genetics: from the bench to the clinic. Neuron 2014, 83:11-26.
23. Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002, 35:843-854.
24. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53.
25. Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.H., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
26. Landles C., Sathasivam K., Weiss A., Woodman B., Moffitt H., Finkbeiner S., Sun B., Gafni J., Ellerby L.M., Trottier Y., et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J.Biol. Chem. 2010, 285:8808-8823.
27. Lee C.Y.D., Cantle J.P., Yang X.W. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J. 2013, 280:4382-4394.
28. Li H., Li S.H., Cheng A.L., Mangiarini L., Bates G.P., Li X.J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 1999, 8:1227-1236.
29. Lunkes A., Lindenberg K.S., Ben-Haïem L., Weber C., Devys D., Landwehrmeyer G.B., Mandel J.L., Trottier Y. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 2002, 10:259-269.
30. Maiuri T., Woloshansky T., Xia J., Truant R. The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal. Hum. Mol. Genet. 2013, 22:1383-1394.
31. Miller J.A., Cai C., Langfelder P., Geschwind D.H., Kurian S.M., Salomon D.R., Horvath S. Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinformatics 2011, 12:322.
32. Mishra R., Hoop C.L., Kodali R., Sahoo B., van der Wel P.C.A., Wetzel R. Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. J.Mol. Biol. 2012, 424:1-14.
33. Moller T. Neuroinflammation in Huntington's disease. J.Neural Transm. 2010, 117:1001-1008.
34. Neveklovska M., Clabough E.B., Steffan J.S., Zeitlin S.O. Deletion of the huntingtin proline-rich region does not significantly affect normal huntingtin function in mice. J.Huntingtons Dis. 2012, 1:71-87.
35. Oldham M.C., Konopka G., Iwamoto K., Langfelder P., Kato T., Horvath S., Geschwind D.H. Functional organization of the transcriptome in human brain. Nat. Neurosci. 2008, 11:1271-1282.
36. Omi K., Hachiya N.S., Tanaka M., Tokunaga K., Kaneko K. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein. Neurosci. Lett. 2008, 431:45-50.
37. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007, 30:575-621.
38. Rockabrand E., Slepko N., Pantalone A., Nukala V.N., Kazantsev A., Marsh J.L., Sullivan P.G., Steffan J.S., Sensi S.L., Thompson L.M. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 2007, 16:61-77.
39. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
40. Ross C.A., Aylward E.H., Wild E.J., Langbehn D.R., Long J.D., Warner J.H., Scahill R.I., Leavitt B.R., Stout J.C., Paulsen J.S., et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 2014, 10:204-216.
41. Rotshenker S. The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease. J.Mol. Neurosci. 2009, 39:99-103.
42. Sathasivam K., Woodman B., Mahal A., Bertaux F., Wanker E.E., Shima D.T., Bates G.P. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Hum. Mol. Genet. 2001, 10:2425-2435.
43. Sathasivam K., Neueder A., Gipson T.A., Landles C., Benjamin A.C., Bondulich M.K., Smith D.L., Faull R.L., Roos R.A., Howland D., et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. USA 2013, 110:2366-2370.
44. Shirasaki D.I., Greiner E.R., Al-Ramahi I., Gray M., Boontheung P., Geschwind D.H., Botas J., Coppola G., Horvath S., Loo J.A., Yang X.W. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 2012, 75:41-57.
45. Sopher B.L., Thomas P.S., LaFevre-Bernt M.A., Holm I.E., Wilke S.A., Ware C.B., Jin L.W., Libby R.T., Ellerby L.M., La Spada A.R. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 2004, 41:687-699.
46. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
47. Tam S., Spiess C., Auyeung W., Joachimiak L., Chen B., Poirier M.A., Frydman J. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat. Struct. Mol. Biol. 2009, 16:1279-1285.
48. Tartari M., Gissi C., Lo Sardo V., Zuccato C., Picardi E., Pesole G., Cattaneo E. Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol. Biol. Evol. 2008, 25:330-338.
49. Thakur A.K., Jayaraman M., Mishra R., Thakur M., Chellgren V.M., Byeon I.-J.L., Anjum D.H., Kodali R., Creamer T.P., Conway J.F., et al. Polyglutamine disruption of the huntingtin exon 1N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 2009, 16:380-389.
50. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
51. Thompson L.M., Aiken C.T., Kaltenbach L.S., Agrawal N., Illes K., Khoshnan A., Martinez-Vincente M., Arrasate M., O'Rourke J.G., Khashwji H., et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J.Cell Biol. 2009, 187:1083-1099.
52. van der Burg J.M., Björkqvist M., Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009, 8:765-774.
53. Van Raamsdonk J.M., Murphy Z., Selva D.M., Hamidizadeh R., Pearson J., Petersén A., Björkqvist M., Muir C., Mackenzie I.R., Hammond G.L., et al. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007, 26:512-520.
54. Vonsattel J.P.G., DiFiglia M. Huntington disease. J.Neuropathol. Exp. Neurol. 1998, 57:369-384.
55. Wang N., Gray M., Lu X.H., Cantle J.P., Holley S.M., Greiner E., Gu X., Shirasaki D., Cepeda C., Li Y., et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat. Med. 2014, 20:536-541.
56. Woodman B., Butler R., Landles C., Lupton M.K., Tse J., Hockly E., Moffitt H., Sathasivam K., Bates G.P. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 2007, 72:83-97.
57. Wyszynski M., Lin J., Rao A., Nigh E., Beggs A.H., Craig A.M., Sheng M. Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Nature 1997, 385:439-442.
58. Yang X.W., Model P., Heintz N. Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome. Nat. Biotechnol. 1997, 15:859-865.
59. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 1995, 11:155-163.
60. Zhang B., Horvath S. A general framework for weighted gene co-expression network analysis. Stat. Appl. Genet. Mol. Biol. 2005, 4:e17.
61. Zheng S., Clabough E.B., Sarkar S., Futter M., Rubinsztein D.C., Zeitlin S.O. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet. 2010, 6:e1000838.
62. Zheng Z., Li A., Holmes B.B., Marasa J.C., Diamond M.I. An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. J.Biol. Chem. 2013, 288:6063-6071.